Dhereputics has theoretically developed a glucose-responsive insulin-delivery vessel, engineered to address diabetes management using advanced nanotechnology and biomaterials through an integration of PLGA polymers, hydrogels and other clinically approved and trialled nanoparticle systems.

The vessel is designed to autonomously detect blood glycogen and, therefore, glucose fluctuations and provide a rapid pulsation of insulin release when directly required.

Our mission is to improve the quality of life, removing multiple daily injections with a single subcutaneous treatment with a functioning life of six months. Leading to only two patient-administered injections per year, designed to provide sustained glucose and insulin regulation and a long-term therapeutic alternative to diabetes management.